- Title: Subtitle
- 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
- Creators
- Julie M. Vose - University of Nebraska Medical CenterChan Y. Cheah - Sir Charles Gairdner HospitalMichael Roost Clausen - Vejle SygehusDavid Cunningham - Royal Marsden NHS Foundation TrustUmar Farooq - University of IowaTatyana Feldman - Hackensack Meridian HealthHerve Ghesquieres - Hôpital Lyon SudWojciech JurczakKim Linton - University of ManchesterCatherine Thieblemont - Hôpital Saint-LouisTycel J. Phillips - University of MichiganWon Seog Kim - Samsung Medical CenterPegah Jafarinasabian - AbbVie (United States)Barbara D'Angelo MånssonDavid Soong - Genmab (United States)Andrew J. Steele - Genmab (United States)Zhu Li - Genmab (United States)Christian Eskelund - Genmab (Denmark)Martin Hutchings - RigshospitaletYasmin H. Karimi - University of Michigan
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.144(Supplement 1), pp.4480-4480
- DOI
- 10.1182/blood-2024-198714
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/05/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984770890902771
Abstract
3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
Blood, Vol.144(Supplement 1), pp.4480-4480
11/05/2024
DOI: 10.1182/blood-2024-198714
Details
Metrics
43 Record Views